Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
复制标题
改良FOLFIRINOX与吉西他滨联合白蛋白结合型紫杉醇作为晚期胰腺癌一线化疗的Meta分析和间接治疗比较
DOI：
10.1186/s12885-021-08605-x
复制
发表时间：
2021-07-23
期刊：
影响因子：
3.8
通讯作者：
Lin Z
中科院分区：
文献类型：
--
作者：
Chen J;Hua Q;Wang H;Zhang D;Zhao L;Yu D;Pi G;Zhang T;Lin Z
改良的FOLFIRINOX和吉西他滨联合NAB(GEM-NAB)已被推荐为晚期胰腺癌(PC)的一线治疗方案。由于缺乏直接比较它们的证据，我们进行了这一网络荟萃分析，以间接比较改良的FOLFIRINOX和GEM-NAB的疗效和毒性。检索并评价截至2020年4月4日与改良FOLFIRINOX和GEM-NAB治疗相关的符合条件的回顾性研究。采用频数模型对不同治疗方案间的生存和毒性资料进行分析。对总生存期(OS)、无进展生存期(PFS)、客观有效率(ORR)和毒性事件进行综合分析。22项研究参与了这一网络荟萃分析。OS与PFS比较，改良FOLFIRINOX与GEM-NAB疗效相近(OS：1.13；95%CI：0.78~1.63；PFS：HR：1.19；95%CI：0.85~1.67)。ORR结果显示，GEM-NAB较改良FOLFIRINOX更有效(RR：1.43；95%CI：1.04~1.96)。此外，我们的分析显示，改良的FOLFIRINOX和GEM-NAB的毒性曲线相似。现有证据表明，经修饰的FOLFIRINOX与GEM-NAB在存活率和毒性方面相似。在制定最佳治疗方案时需要考虑许多因素，我们的荟萃分析可以为晚期PC一线治疗方案的选择提供一定的指导。网上版载有补充材料，可在10.1186/s12885-021-08605-x查阅。
Modified FOLFIRINOX and gemcitabine plus nab-paclitaxel (GEM-NAB) have been recommended as first-line therapies for advanced pancreatic cancer (PC). Due to the lack of evidence to directly compare them, we conducted this network meta-analysis to indirectly compare the effectiveness and toxicity of modified FOLFIRINOX and GEM-NAB. The eligible retrospective studies on treatments related to modified FOLFIRINOX and GEM-NAB up to 4 April 2020 were searched and assessed. We used the frequentist model to analyze the survival and toxicity data between different treatments. Pooled analysis for overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and events of toxicity were analyzed in this study. Twenty-two studies were involved in this network meta-analysis. The comparisons on OS and PFS showed that modified FOLFIRINOX and GEM-NAB had similar treatment efficacy (OS: 1.13; 95% CI: 0.78–1.63; PFS: HR: 1.19; 95% CI: 0.85–1.67). GEM-NAB was more effective than modified FOLFIRINOX based on the result of ORR (RR: 1.43; 95% CI: 1.04–1.96). Moreover, our analysis showed a similar toxicity profile between modified FOLFIRINOX and GEM-NAB. The current evidence showed that modified FOLFIRINOX and GEM-NAB were similar in survival and toxicity. Many factors should be considered for in the formulation of optimal treatment, and our meta-analysis could provide some guidance to treatment selection in the first-line setting for advanced PC. The online version contains supplementary material available at 10.1186/s12885-021-08605-x.
登录
查看更多内容
影响因子：
3.8
作者：
Kim S;Signorovitch JE;Yang H;Patterson-Lomba O;Xiang CQ;Ung B;Parisi M;Marshall JL
通讯作者：
Marshall JL
影响因子：
2.1
作者：
Muranaka, Tetsuhito;Kuwatani, Masaki;Sakamoto, Naoya
通讯作者：
Sakamoto, Naoya
影响因子：
45.3
作者：
Gourgou-Bourgade, Sophie;Bascoul-Mollevi, Caroline;Conroy, Thierry
通讯作者：
Conroy, Thierry
影响因子：
4.4
作者：
Kim, George P.;Parisi, Monika F.;Belk, Kathy W.
通讯作者：
Belk, Kathy W.
影响因子：
2
作者：
Dias, S.;Welton, N. J.;Ades, A. E.
通讯作者：
Ades, A. E.